Acute chemotherapy – related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res. 2006; 12 :7033–6.Shanley S, McReynolds K, Ardern-Jones A, et al. Acute chemotherapy-related toxicity is not increased in BRCA1 ...
The standard treatment for these group is chemotherapy. The alternative treatment could be combination therapy of chemotherapy and bevacizumab, the recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF) [3,9]. 1.1 Biomarkers In the case of breast cancer, the most ...
摘要: Treatment with (neo)adjuvant chemotherapy for breast cancer, as currently given, causes cell damage by induction of double-strand DNA breaks. Because BRCA1 and BRCA2 proteins play ... 查看全部>>关键词:Chemotherapy BRCA mutation Toxicity Breast cancer Dose intensity ...
followed by 4 cycles of taxane and trastuzumab (P + EC-TH) regimen as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer and to investigate the predictive value of p53, p63, and epidermal growth factor receptor (EGFR) status for neoadjuvant ...
Abbreviations:BC = breast cancer; PBS = primary breast surgery; NACT = neoadjuvant chemotherapy; T2+: tumor size >2 cmin diameter. a Calculated with a multivariable model adjusting also for center. 3.1. Determinants of NACT The overall incidence of NACT increased significantly from 2017 to 2022...
genes have been implicated in increased risk of pancreatic cancer (Hruban et al, 2010), mutations in the breast cancer early onset (BRCA1 & BRCA2) tumour suppressor genes are currently the best characterised and appear to be to be responsible for B15% of familial cases (Couch et al, 2007...
1.The treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues. 2.The treatment of disease using chemical agents or drugs that are selectively toxic to the causative agent of the disease, such as a virus, bacterium, or other mic...
(D) Distribution of BRCA2 mutant allele frequencies for 6 TM00099 xenograft samples as measured by exome-seq cancer panel. The mean and standard deviation of mutant allele frequency are 0.545 ± 0.015. (E) Spatial dissection of the P2 passage of tumor TM00096. (F) Mutations predicted...
HR+/HER2– breast cancer is the most common subtype of breast cancer Chemotherapy is utilized widely for management of endocrine-resistant HR+/HER2– MBC,but is associated with low response rate, poor prognosis, and significant toxicity TROP2-directed ADCs can have...
Fig. 1. Flow diagram of inclusion criteria for the subanalysis. BC, breast cancer; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; NAC, neoadjuvant chemotherapy; pCR, pathological complete response; TNBC, triple-negative breast...